Chronic Idiopathic Urticaria

Dupilumab did not reach statistical significance in interim analysis despite numeric improvements being observed across key endpoints.

Though the severity of the COVID-19 virus did not differ in participants with different dermatological conditions, their conditions were affected in alternate ways.

Investigators believe their study shows the efficacy and safety of the 2 biologic agents, which are known to have anti-inflammatory and immunosuppressant qualities.

The Phase 2b study shows a higher proportion of ligelizumab-treated patients achieved complete response or lower severity score compared with omalizumab.

The approval of the sBLA means greater flexibility and reduced barriers in care during the pandemic.

The 5 companies issued letters will have 15 days to submit a compliance plan.

The FDA approvals of biologics for atopic dermatitis and psoriasis have ushered in a new era for the once-stagnant field of pediatric dermatology.

Approval allows Almirall to move forward with the topical ointment for individuals with AK on the face or scalp.

In new phase 3b findings, a greater proportion of patients treated with upadacitinib achieved EASI 75 at week 16 than those who received dupilumab.

There is a gap between the efficacy of biologics in trials and the real-world setting.

Strict avoidance of systemic corticosteroids among patients with psoriasis may be unnecessary.

Largest study of multiple health indicators over time finds widening disparities in health by race, despite increased targeted funding.

The risk of suicidality and psychological adverse events appears to be particularly high in younger men with alopecia who are given finasteride.

Newborns who were given a probiotic had lower rates of atopic dermatitis and lower symptom scores, according to a new study.

A new study confirms the link between chronic urticaria and fibromyalgia, though the correlation is not as strong as in a previous study.

The incidence or urticaria in patients does not depend on exposure to air pollution.

Favorable phase 2 results with the TYK2 inhibitor for psoriatic arthritis at ACR 2020 coincided with announced positive phase 3 trial results for psoriasis.

Drugs often trigger outbreaks of hives, but investigators observed no clear evidence as to the overall incidence of drug allergies in CSU.

Patients who are prescribed metformin may face a risk of urticaria, though the latter can be treated with antihistamines.

FDA application is based on the positive data from 3 recent phase 3 clinical trials.

Only 29.5% of sampled CBD users claimed any wellness benefit.

Many patients do not see meaningful improvement with the current standard treatment. New data suggest this monoclonal antibody might be a better choice.

A higher proportion of risankizumab users achieved improved measures for symptoms, quality of life, and mental health versus comparators.

Though atopic dermatitis is a relatively common condition, most of the existing scientific literature has ignored the majority of patients who have mild or limited disease.

About 69% of patients with CIU were either obese or overweight, and experienced a longer duration of disease than those who had lower weight values.

New research suggests the Janus kinase 1 and 2 inhibitor relieves symptoms of atopic dermatitis at a daily dose of 4 mg.

Newly published data show routine testing is unlikely to change the management of patients with CSU.

Both antihistamines are indicated for treatment of chronic idiopathic urticaria, yet olopatadine demonstrates better clinical improvements and fewer adverse events.

Patients impacted by pruritus were more depressed and anxious than a comparison control group.

More studies are needed on the effectiveness and safety of plaque psoriasis therapies for older patients.